Promoter Hypermethylation in Prostate Cancer

Crawford E.D. . Epidemiology of prostate cancer. Urology. 2003; 62(6 suppl 1): 3–12.

Jemal A. , Siegel R. , Xu J. . Cancer statistics, 2010. CA Cancer J Clin. 2010 Jul 7. Epub ahead of print.

Baylin S.B. , Herman J.G. . DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000; 16(4): 168–174.

Smiraglia D.J. , Plass C. . The study of aberrant methylation in cancer via restriction landmark genomic scanning. Oncogene. 2002; 21(35): 5414–5426.

Rush L.J. , Dai Z. , Smiraglia D.J. . Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci. Blood. 2001; 97(10): 3226–3233.

Costello J.F. , Frühwald M.C. , Smiraglia D.J. . Aberrant CpG-island methylation has nonrandom and tumour-type-specific patterns. Nat Genet. 2000; 24(2): 132–138.

Frühwald M.C. , O'Dorisio M.S. , Dai Z. . Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas: implications for tumor biology and potential clinical utility. Oncogene. 2001; 20(36): 5033–5042.

Baylin S.B. , Herman J.G. , Graff J.R. . Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998; 72: 141–196.

Sulewska A. , Niklinska W. , Kozlowski M. . Detection of DNA methylation in eucaryotic cells. Folia Histochem Cytobiol. 2007; 45(4): 315–324.

Tanaka K. , Okamoto A. . Degradation of DNA by bisulfite treatment. Bioorg Med Chem Lett. 2007; 17(7): 1912–1915.

Park J.Y. , Zheng W. , Kim D. . Candidate tumor suppressor gene SLC5A8 is frequently downregulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev. 2007; 31(5): 359–365.

Esteller M. . Epigenetics in cancer. N Engl J Med. 2008; 358(11): 1148–1159.

Friedberg E.C. . How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001; 1(1): 22–33.

Mullaart E. , Lohman P.H. , Berends F. . DNA damage metabolism and aging. Mutat Res. 1990; 237(5-6): 189–210.

Wood R.D. , Mitchell M. , Lindahl T. . Human DNA repair genes, 2005. Mutat Res. 2005;577(1-2): 275–283.

Park J.Y. , Huang Y. , Sellers T.A. . Single nucleotide polymorphisms in DNA repair genes and prostate cancer risk. Methods Mol Biol. 2009; 471: 361–385.

Maruyama R. , Toyooka S. , Toyooka K.O. . Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res. 2002; 8(2): 514–519.

Yamanaka M. , Watanabe M. , Yamada Y. . Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer. 2003; 106(3): 382–387.

Yegnasubramanian S. , Kowalski J. , Gonzalgo M.L. . Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004; 64(6): 1975–1986.

Jerónimo C. , Henrique R. , Hoque M.O. . A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res. 2004; 10(24): 8472–8478.

Konishi N. , Nakamura M. , Kishi M. . DNA hypermethylation status of multiple genes in prostate adenocarcinomas. Jpn J Cancer Res. 2002; 93(7): 767–773.

Kang G.H. , Lee S. , Lee H.J. . Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol. 2004; 202(2): 233–240.

Li L.C. , Okino S.T. , Dahiya R. . DNA methylation in prostate cancer. Biochim Biophys Acta. 2004; 1704(2): 87–102.

Nguyen T.T. , Nguyen C.T. , Gonzales F.A. . Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers. Prostate. 2000; 43(3): 233–242.

Jarrard D.F. , Bova G.S. , Ewing C.M. . Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer. 1997; 19(2): 90–96.

Gu K. , Mes-Masson A.M. , Gauthier J. . Analysis of the p16 tumor suppressor gene in early-stage prostate cancer. Mol Carcinog. 1998; 21(3): 164–170.

Hoque M.O. , Topaloglu O. , Begum S. . Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol. 2005; 23(27): 6569–6575.

Florl A.R. , Steinhoff C. , Müller M. . Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer. 2004; 91(5): 985–994.

Herman J.G. , Merlo A. , Mao L. . Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995; 55(20): 4525–4530.

Nakamura M. , Watanabe T. , Klangby U. . p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol. 2001; 11(2): 159–168.

Lin H.H. , Ke H.L. , Huang S.P. . Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. Urol Oncol. 2009 Jan 30. Epub ahead of print.

Chim C.S. , Chan W.W. , Kwong Y.L. . Epigenetic dysregulation of the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in acute leukaemias. J Clin Pathol. 2008; 61(7): 844–847.

Calmon M.F. , Colombo J. , Carvalho F. . Methylation profile of genes CDKN2A (p14 and p16), DAPK1, CDH1, and ADAM23 in head and neck cancer. Cancer Genet Cytogenet. 2007; 173(1): 31–37.

Konishi N. , Nakamura M. , Kishi M. . Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. Am J Pathol. 2002; 160(4): 1207–1214.

Rouprêt M. , Hupertan V. , Yates D.R. . Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res. 2007; 13(6): 1720–1725.

Kuzmin I. , Gillespie J.W. , Protopopov A. . The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res. 2002; 62(12): 3498–3502.

Liu L. , Yoon J.H. , Dammann R. . Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene. 2002; 21(44): 6835–6840.

Kawamoto K. , Okino S.T. , Place R.F. . Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res. 2007; 13(9): 2541–2548.

Singal R. , Ferdinand L. , Reis I.M. . Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep. 2004; 12(3): 631–637.

Woodson K. , Hanson J. , Tangrea J. . A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett. 2004; 205(2): 181–188.

Woodson K. , Hayes R. , Wideroff L. . Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate. 2003; 55(3): 199–205.

Padar A. , Sathyanarayana U.G. , Suzuki M. . Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin Cancer Res. 2003; 9(13): 4730–4734.

Henrique R. , Costa V.L. , Cerveira N. . Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med. 2006; 84(11): 911–918.

Hussain S.P. , Harris C.C. . Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007; 121(11): 2373–2380.

Bastian P.J. , Ellinger J. , Wellmann A. . Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res. 2005; 11(11): 4097–4106.

Kito H. , Suzuki H. , Ichikawa T. . Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate. 2001; 49(2): 110–115.

Gao X. , Porter A.T. , Honn K.V. . Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer: therapeutic implications. Adv Exp Med Biol. 1997; 407: 41–53.

Rosenbaum E. , Hoque M.O. , Cohen Y. . Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res. 2005; 11(23): 8321–8325.

Kim J.W. , Cheng Y. , Liu W. . Genetic and epigenetic inactivation of LPL gene in human prostate cancer. Int J Cancer. 2009; 124(3): 734–738.

Chen W.Y. , Zeng X. , Carter M.G. . Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet. 2003; 33(2): 197–202.

Chen W. , Cooper T.K. , Zahnow C.A. . Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell. 2004; 6(4): 387–398.

Weiss G. , Cottrell S. , Distler J. . DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol. 2009; 181(4): 1678–1685.

Hampton T. . New markers may help predict prostate cancer relapse risk. JAMA. 2006; 295(19): 2234–2238.

Vanaja D.K. , Ehrich M. , Van den Boom D. . Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest. 2009; 27(5): 549–560.

Bastian P.J. , Ellinger J. , Heukamp L.C. . Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol. 2007; 51(3): 665–674; discussion 674.

Lou W. , Krill D. , Dhir R. . Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res. 1999; 59(10): 2329–2331.

Nelson J.B. , Lee W.H. , Nguyen S.H. . Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res. 1997; 57(1): 35–37.

Jerónimo C. , Henrique R. , Campos P.F. . Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J Clin Pathol. 2003; 56(1): 52–55.

Ellinger J. , Bastian P.J. , Jurgan T. . CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology. 2008; 71(1): 161–167.

Kekeeva T.V. , Popova O.P. , Shegaî P.V. . Aberrant methylation of p16, HIC1, N33 and GSTP1 genes in tumor epitelium and tumor-associated stromal cells of prostate cancer [in Russian]. Mol Biol (Mosk). 2007; 41(1): 79–85.

Murphy T.M. , Perry A.S. , Lawler M. . The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. Endocr Relat Cancer. 2008; 15(1): 11–25.

Park J. , Brena R.M. , Gruidl M. . CpG island hypermethylation profiling of lung cancer using restriction landmark genomic scanning (RLGS) analysis. Cancer Biomark. 2005; 1(2-3): 193–200.

Sørensen K.D. , Wild P.J. , Mortezavi A. . Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res. 2009; 15(4): 1400–1410.

Shivapurkar N. , Toyooka S. , Toyooka K.O. . Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer. 2004; 109(5): 786–792.

van Noesel M.M. , van Bezouw S. , Salomons G.S. . Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res. 2002; 62(7): 2157–2161.

Cho N.Y. , Kim B.H. , Choi M. . Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol. 2007; 211(3): 269–277.

Cheng Y. , Kim J.W. , Liu W. . Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer. Prostate. 2009; 69(3): 327–335.

Hornstein M. , Hoffmann M.J. , Alexa A. . Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer. Cancer Genomics Proteomics. 2008; 5(2): 123–136.

Henderson B.E. , Ross R.K. , Pike M.C. . Endogenous hormones as a major factor in human cancer. Cancer Res. 1982; 42(8): 3232–3239.

Henderson B.E. , Ross R.K. , Pike M.C. . Toward the primary prevention of cancer. Science. 1991; 254(5035): 1131–1138.

Wang Q. , Li W. , Zhang Y. . Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009; 138(2): 245–256.

Eder I.E. , Culig Z. , Ramoner R. . Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther. 2000; 7(7): 997–1007.

Mitchell S.H. , Zhu W. , Young C.Y. . Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 1999; 59(23): 5892–5895.

Tong Q. , Zeng F. , Lin C. . Growth inhibiting effects of antisense eukaryotic expression vector of proliferating cell nuclear antigen gene on human bladder cancer cells. Chin Med J (Engl). 2003; 116(8): 1203–1206.

Heisler L.E. , Evangelou A. , Lew A.M. . Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol. 1997; 126(1): 59–73.

Feldman B.J. , Feldman D. . The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001; 1(1): 34–45.

Grossmann M.E. , Huang H. , Tindall D.J. . Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst. 2001; 93(22): 1687–1697.

Kinoshita H. , Shi Y. , Sandefur C. . Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res. 2000; 60(13): 3623–3630.

Sasaki M. , Tanaka Y. , Perinchery G. . Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst. 2002; 94(5): 384–390.

Nakayama T. , Watanabe M. , Suzuki H. . Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest. 2000; 80(12): 1789–1796.

Reibenwein J. , Pils D. , Horak P. . Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate. 2007; 67(4): 427–432.

Ho S.M. , Tang W.Y. , Belmonte de Frausto J. . Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res. 2006; 66(11): 5624–5632.

Hobisch A. , Hittmair A. , Daxenbichler G. . Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J Pathol. 1997; 182(3): 356–361.

Horvath L.G. , Henshall S.M. , Lee C.S. . Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res. 2001; 61(14): 5331–5335.

Zhu X. , Leav I. , Leung Y.K. . Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol. 2004; 164(6): 2003–2012.

Zhang X. , Leung Y.K. , Ho S.M. . AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0N promoter in prostate cancer cells. Oncogene. 2007; 26(52): 7346–7354.

Konishi N. , Nakaoka S. , Hiasa Y. . Immunohistochemical evaluation of estrogen receptor status in benign prostatic hypertrophy and in prostate carcinoma and the relationship to efficacy of endocrine therapy. Oncology. 1993; 50(4): 259–263.

Leav I. , Lau K.M. , Adams J.Y. . Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol. 2001; 159(1): 79–92.

Li L.C. , Chui R. , Nakajima K. . Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res. 2000; 60(3): 702–706.

Nojima D. , Li L.C. , Dharia A. . CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma. Cancer. 2001; 92(8): 2076–2083.

Yao Q. , He X.S. , Zhang J.M. . Promotor hypermethylation of Ecadherin, p16 and estrogen receptor in prostate carcinoma [in Chinese]. Zhonghua Nan Ke Xue. 2006; 12(1): 28–31.

Hayashi K. , Yokozaki H. , Naka K. . Overexpression of retinoic acid receptor beta induces growth arrest and apoptosis in oral cancer cell lines. Jpn J Cancer Res. 2001; 92(1): 42–50.

Nakayama T. , Watanabe M. , Yamanaka M. . The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab Invest. 2001; 81(7): 1049–1057.

Zhang J. , Liu L. , Pfeifer G.P. . Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene. Oncogene. 2004; 23(12): 2241–2249.

Nelson C.P. , Kidd L.C. , Sauvageot J. . Protection against 2-hydrox-yamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res. 2001; 61(1): 103–109.

Lee W.H. , Morton R.A. , Epstein J.I. . Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A. 1994; 91(24): 11733–11737.

Harden S.V. , Guo Z. , Epstein J.I. . Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol. 2003; 169(3): 1138–1142.

Cairns P. , Esteller M. , Herman J.G. . Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res. 2001 7(9): 2727–2730.

Lee W.H. , Isaacs W.B. , Bova G.S. . CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev. 1997; 6(6): 443–450.

Santourlidis S. , Florl A. , Ackermann R. . High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate. 1999; 39(3): 166–174.

Goessl C. , Krause H. , Müller M. . Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 2000; 60(21): 5941–5945.

Jerónimo C. , Usadel H. , Henrique R. . Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst. 2001; 93(22): 1747–1752.

Gonzalgo M.L. , Pavlovich C.P. , Lee S.M. . Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res. 2003; 9(7): 2673–2677.

Jerónimo C. , Varzim G. , Henrique R. . I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2002; 11(5): 445–450.

Köllermann J. , Müller M. , Goessl C. . Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients. Eur Urol. 2003; 44(5): 533–538.

Goessl C. , Müller M. , Heicappell R. . DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann N Y Acad Sci. 2001; 945: 51–58.

Suh C.I. , Shanafelt T. , May D.J. . Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer. Mol Cell Probes. 2000; 14(4): 211–217.

Esteller M. , Guo M. , Moreno V. . Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer. Cancer Res. 2002; 62(20): 5902–5905.

Jerónimo C. , Henrique R. , Oliveira J. . Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer. J Clin Pathol. 2004; 57(8): 872–876.

Tokumaru Y. , Sun D.I. , Nomoto S. . Re: Is TIG1 a new tumor suppressor in prostate cancer? J Natl Cancer Inst. 2003; 95(12): 919–920.

Topaloglu O. , Hoque M.O. , Tokumaru Y. . Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res. 2004; 10(7): 2284–2288.

Ellinger J. , Haan K. , Heukamp L.C. . CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate. 2008; 68(1): 42–49.

Bastian P.J. , Palapattu G.S. , Yegnasubramanian S. . CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol. 2008; 179(2): 529–534; discussion 534-535.

Baylin S.B. , Ohm J.E. . Epigenetic gene silencing in cancer: a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006; 6(2): 107–116.

Henrique R. , Ribeiro F.R. , Fonseca D. . High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res. 2007; 13(20): 6122–6129.

Tokumaru Y. , Harden S.V. , Sun D.I. . Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res. 2004; 10(16): 5518–5522.

Enokida H. , Shiina H. , Urakami S. . Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res. 2005; 11(18): 6582–6588.

Richiardi L. , Fiano V. , Vizzini L. . Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol. 2009; 27(19): 3161–3168.

Gokaslan Z.L. , Chintala S.K. , York J.E. . Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors. Clin Exp Metastasis. 1998; 16(8): 721–728.

Gomez D.E. , Alonso D.F. , Yoshiji H. . Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997; 74(2): 111–122.

Imren S. , Kohn D.B. , Shimada H. . Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res. 1996; 56(13): 2891–2895.

Mohanam S. , Wang S.W. , Rayford A. . Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Clin Exp Metastasis. 1995; 13(1): 57–62.

Pulukuri S.M. , Patibandla S. , Patel J. . Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene. 2007; 26(36): 5229–5237.

Ross J.S. , Kaur P. , Sheehan C.E. . Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol. 2003; 16(3): 198–205.

Han X. , Zhang H. , Jia M. . Expression of TIMP-3 gene by construction of a eukaryotic cell expression vector and its role in reduction of metastasis in a human breast cancer cell line. Cell Mol Immunol. 2004; 1(4): 308–310.

Deng X. , Bhagat S. , Dong Z. . Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel. Eur J Cancer. 2006; 42(18): 3267–3273.

Finan K.M. , Hodge G. , Reynolds A.M. . In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2. Lung Cancer. 2006 53(3): 273–284.

Smith E. , De Young N.J. , Tian Z.Q. . Methylation of TIMP3 in esophageal squamous cell carcinoma. World J Gastroenterol. 2008; 14(2): 203–210.

Bachmann N. , Haeusler J. , Luedeke M. . Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma. Cancer Genet Cyto-genet. 2008; 182(2): 103–110.

Cui J. , Rohr L.R. , Swanson G. . Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate. 2001; 46(3): 249–256.

Li L.C. , Zhao H. , Nakajima K. . Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. J Urol. 2001; 166(2): 705–709.

Alumkal J.J. , Zhang Z. , Humphreys E.B. . Effect of DNA methylation on identification of aggressive prostate cancer. Urology. 2008; 72(6): 1234–1239.

Oudes A.J. , Roach J.C. , Walashek L.S. . Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression. BMC Cancer. 2005; 5: 86.

Rehman I. , Cross S.S. , Catto J.W. . Promoter hypermethylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer. Prostate. 2005; 65(4): 322–330.

Guan M. , Xu C. , Zhang F. . Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int J Cancer. 2009; 124(1): 88–94.

Karam J.A. , Lotan Y. , Roehrborn C.G. . Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate. 2007; 67(6): 614–622.

Lee S.W. . H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. Nat Med. 1996; 2(7): 776–782.

Mack G.S. . Epigenetic cancer therapy makes headway. J Natl Cancer Inst. 2006; 98(20): 1443–1444.

Müller C.I. , Rüter B. , Koeffler H.P. . DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML. Curr Pharm Biotechnol. 2006; 7(5): 315–321.

Oki Y. , Aoki E. , Issa J.P. . Decitabine: bedside to bench. Crit Rev Oncol Hematol. 2007; 61(2): 140–152.

Müller A. , Florek M. . 5-Azacytidine/Azacitidine. Recent Results Cancer Res. 2010; 184: 159–170.